natgillin/translations-raw huggingface dataset:
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):
V sledečih okoliščinah lahko vodenje vaše sladkorne bolezni zahteva posebno skrb (npr. prilagoditev odmerka insulina, preiskave krvi in urina):
In the following situations, the management of your diabetes may require a lot of care:
V sledečih okoliščinah lahko vodenje vaše sladkorne bolezni zahteva posebno skrb:
In the following situations, the management of your diabetes may require extra care (e.g. urine and blood tests):
V naslednjih okoliščinah lahko vodenje vaše sladkorne bolezni zahteva dodatno skrb (npr. teste urina in krvi):
In the following situations, the management of your diabetes may require extra care:
V sledečih okoliščinah lahko vodenje vaše sladkorne bolezni zahteva posebno skrb:
In the fourth study in adults who had not responded to lamivudine treatment, Viread was effective when given alone: 89% of patients taking Viread had a viral level below 400 copies/ml after 96 weeks of treatment, compared with 86% of patients taking the combination treatment of Viread and emtricitabine.
V četrti študiji pri odraslih, ki se niso odzvali na zdravljenje z lamivudinom, je bilo zdravilo Viread učinkovito, kadar se je jemalo kot samostojno zdravilo: pri 89 % bolnikov, ki so jemali zdravilo Viread, je bilo virusno breme po 96 tednih zdravljenja pod 400 kopijami/ml v primerjavi s 86 % bolnikov, ki so jemali kombinacijo zdravila Viread in emtricitabina.
In the fourth study in patients with the R117H mutation, no difference was seen between placebo and Kalydeco for children aged 6 years and above.
V četrti študiji pri bolnikih z mutacijo R117H ni bilo razlike med placebom in zdravilom Kalydeco pri otrocih, starejših od šest let.
In the fourth study, in lung cancer patients who had not responded to previous chemotherapy, the patients taking Tarceva survived for an average of 6.7 months, compared with 4.7 months for the patients taking placebo.
V četrti študiji, ki je vključevala bolnike s pljučnim rakom, ki se niso odzvali na predhodne kemoterapije, so bolniki, ki so jemali zdravilo Tarceva, v povprečju preživeli 6,7 meseca, tisti, ki so jemali placebo, pa 4,7 meseca.
In the fourth study, Multaq was less effective than amiodarone at maintaining normal rhythm: after a year, atrial fibrillation had come back or treatment had been stopped in 75% of the patients taking Multaq, compared with 59% of the patients receiving amiodarone.
V četrti študiji je bilo zdravilo Multaq pri vzdrževanju normalnega ritma manj učinkovito kot amiodaron: po enem letu se je atrijska fibrilacija ponovila ali je bilo zdravljenje prekinjeno pri 75 % bolnikov, ki so jemali zdravilo Multaq, v primerjavi z 59 % bolnikov, ki so prejemali amiodaron.
In the fourth study, Orencia in combination with methotrexate was compared with Orencia alone and methotrexate alone in 351 adults who had not been treated with methotrexate (or with any so-called biologic agents such as TNF alpha blockers) in the past, but may have been on other medicines for management of rheumatoid arthritis.
V četrti študiji so zdravilo Orencia skupaj z metotreksatom primerjali z zdravilom Orencia, ki se daje samostojno, pri 351 odraslih, ki v preteklosti niso bili zdravljeni z metotreksatom (ali s katerimi drugimi takoimenovanimi biološkimi učinkovinami, kot so zaviralci tumorje nekrotizirajočega faktorja-alfa), so pa morda jemali druga zdravila za obvladovanje revmatoidnega artritisa.
In the fourth study, previously treated patients with wild-type RAS receiving Vectibix in combination with FOLFIRI lived for 16.2 months compared with 13.9 months in patients receiving FOLFIRI alone.
V četrti študiji so predhodno zdravljeni bolniki z divjim tipom gena RAS, ki so prejemali zdravilo Vectibix v kombinaciji s kemoterapijo FOLFIRI, živeli 16,2 meseca v primerjavi s 13,9 meseca pri bolnikih, ki so prejemali le kemoterapijo FOLFIRI.
In the fourth study, the average reduction with Bydureon was 1.5 points after 26 weeks, compared with an average reduction of 1.3 points with insulin glargine.
V četrti študiji se je po 26 tednih zdravljenja z zdravilom Bydureon raven HbA1c v povprečju znižala za 1,5 točke v primerjavi s povprečnim znižanjem za 1,3 točke pri zdravljenju z insulinom glarginom.
In the fourth study, which included 498 patients who had an inadequate response to TNF blockers, patients receiving RoActemra with methotrexate were around 9 times more likely to respond than those receiving placebo with methotrexate.
V četrti študiji pri 498 bolnikih, ki se niso zadostno odzvali na zaviralce tumorje nekrotizirajočega faktorja, so se tisti, ki so prejemali zdravilo RoActemra z metotreksatom, približno devetkrat pogosteje odzvali na zdravljenje kot tisti, ki so prejemali placebo z metotreksatom.
In the fourth trial, approximately 800 patients (aged  2 years) received 0.1% tacrolimus ointment intermittently or continuously in an open-label, long-term safety study for up to four years, with 300 patients receiving treatment for at least three years and 79 patients receiving treatment for a minimum of 42 months.
V četrti študiji, odprti, dolgoročni raziskavi varnosti, je približno 800 bolnikov (starih  2 leti) do štiri leta intermitentno ali stalno dobivalo 0,1% mazilo s takrolimusom; 300 bolnikov je bilo zdravljenih vsaj tri leta, 79 bolnikov pa je zdravljenje dobivalo najmanj 42 mesecev.
In the future if rabbits are exposed to rabbit haemorrhagic disease type 2 virus, the immune system will be able to produce antibodies more quickly.
Če so kunci pozneje izpostavljeni virusu hemoragične bolezni kuncev tipa 2, lahko imunski sistem hitreje tvori protitelesa proti njej.
In the future, if the
Ob morebitni
In the future, if the
Če bo žival v prihodnosti ponovno
In the future, if the animals are exposed to PCV2, the immune system will be able to produce antibodies more quickly.
Ob ponovni izpostavitvi virusu PCV2 v prihodnosti bo imunski sistem lahko zato hitreje tvoril protitelesa.
In the future, if the animals are exposed to the same type of bluetongue virus, the immune system will be able to produce antibodies more quickly.
Ob ponovni izpostavitvi enaki vrsti virusa bolezni modrikastega jezika v prihodnosti bo imunski sistem tako hitreje tvoril protitelesa.
In the future, if the animals are exposed to the virus or the bacteria the immune system will be able to respond more quickly.
Če so živali pozneje izpostavljene virusu ali bakterijam, se lahko imunski sistem nanje hitreje odzove.
In the future, the immune system will be
Ob ponovni izpostavitvi kateremu od teh virusnih sevov bo imunski sistem lahko hitreje tvoril protitelesa.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these viruses.
Ko bo imunski sistem naslednjič izpostavljen kateremu od teh virusov, bo lahko hitreje tvoril protitelesa.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to FeLV.
Tako bo imunski sistem v prihodnosti sposoben hitreje tvoriti protitelesa, če bo izpostavljen FeLV.
In the future, the immune system will be able to react against the virus more quickly when it is exposed to the virus.
Ob ponovni izpostavitvi virusom v prihodnosti bo imunski sistem reagiral proti virusu hitreje.
In the FUTURE-4 study including 13 neonates with PPHN treated with bosentan 2 mg/kg twice daily for less than 10 days (range 0.5–10.0 days) there were no cases of liver aminotransferases ≥ 3  ULN during treatment but one case of hepatitis occurred 3 days after the end of bosentan treatment.
V študiji FUTURE-4, ki je vključevala 13 novorojenčkov s PPHN, zdravljenih z bosentanom 2 mg/kg dvakrat dnevno manj kot 10 dni (razpon 0,5 – 10,0 dni), ni bilo primerov povišanja jetrnih aminotransferaz ≥ 3  ULN med zdravljenjem, vendar pa je prišlo do enega primera hepatitisa 3 dni po prenehanju zdravljenja z bosentanom.
In the FUTURE-4 study including 13 neonates with PPHN treated with bosentan 2 mg/kg twice daily for less than 10 days (range 0.5–10.0 days) there were no cases of liver aminotransferases ≥ 3  ULN during treatment, but one case of hepatitis occurred 3 days after the end of bosentan treatment.
V študiji FUTURE-4, ki je vključevala 13 novorojenčkov s PPHN, zdravljenih z bosentanom 2 mg/kg dvakrat dnevno manj kot 10 dni (razpon 0,5 – 10,0 dni), ni bilo primerov povišanja jetrnih aminotransferaz ≥ 3  ULN med zdravljenjem, vendar pa je prišlo do enega primera hepatitisa 3 dni po prenehanju zdravljenja z bosentanom.
In the genotype 1a replicon, the activity of dasabuvir was reduced 21- to 32-fold by the M414T, S556G or Y561H substitutions; 152- to 261-fold by the A553T, G554S or S556R substitutions; and 1472- and 975-fold by the C316Y and Y448H substitutions, respectively.
V replikonu genotipa 1a so substitucije M414T, S556G ali Y561H zmanjšale aktivnost dasabuvirja za 21- do 32-krat, substitucije A553T, G554S ali S556R za 152- do 261-krat in substituciji C316Y in Y448H za 1472- in 975-krat.
In the genotype 1a replicon, the activity of ombitasvir was reduced by 896-, 58- and 243-fold against the M28T/V and H58D substitutions, respectively, and 1326-, 800-, 155-foldand 1675- to 66740- fold by the Q30E/R, L31V and Y93C/H/N substitutions, respectively.
V replikonu genotipa 1a so substituciji M28T/V in H58D zmanjšale aktivnost ombitasvirja za 896-,58- in 243-krat, substitucije Q30E/R, L31V in Y93C/H/N pa za 1326-, 800-, 155-krat in 1675- do 66740-krat.
In the GESTURE Study, secukinumab was superior to placebo at Week 16 (33.3% for 300 mg, 22.1% for 150 mg, and 1.5% for placebo) as assessed by significant improvement of ppIGA 0 or 1 response (“clear” or “almost clear”) for patients with moderate to severe palmoplantar plaque psoriasis.
V študiji GESTURE je bil pri bolnikih z zmerno do hudo palmoplantarno psoriazo s plaki sekukinumab boljši od placeba glede na oceno pomembnega izboljšanja od izhodišča do 16. tedna na osnovi ocene ppIGA (izraženost palmoplantarne psoriaze po oceni raziskovalca) oziroma doseganja odziva "0" oziroma "1" ("brez znakov" ali "skoraj brez znakov" prizadetosti) (33,3% pri odmerku 300 mg, 22,1% pri odmerku 150 mg in 1,5% pri uporabi placeba).
In the Glivec arm, patients were treated with 400 mg daily.
Na kraku z zdravilom Glivec so bili bolniki zdravljeni s 400 mg na dan.
In the GLP toxicity studies, with the exception of irreversible peripheral axonal toxicity (observed only in monkeys at  10 mg/kg) and reproductive organ toxicity (observed only in rats at 60 mg/kg), partially or completely reversible dose dependent toxicities were identified in both animal models.
V študijah toksičnosti v skladu z dobro laboratorijsko prakso so v obeh živalskih modelih ugotovili delno ali popolnoma reverzibilne od odmerka odvisne toksične učinke; izjema so bili ireverzibilni periferni aksonski toksični učinki (opaženi le pri opicah ob uporabi  10 mg/kg) in ireverzibilni reproduktivni toksični učinki (opaženi le pri podganah ob uporabi 60 mg/kg).
In the group receiving atazanavir 300 mg co-administered with ritonavir 100 mg, evaluable genotypic data was available for all 12 virologic failures (3%, 12/348) and no subject had emergent resistance to any component of the regimen.
V skupini, ki je prejemala atazanavir v odmerku 300 mg skupaj z ritonavirjem v odmerku 100 mg, so bili na voljo ovrednoteni genotipski podatki za vseh 12 viroloških neuspehov (3 %, 12/348) in noben bolnik ni razvil odpornosti proti katerikoli sestavini režima.
In the group that kept on receiving the GLP-1 agonist, it fell from 7.7% to 7.4%.
V skupini, ki je nadaljevala z jemanjem antagonista GLP-1, se je raven znižala s 7,7 % na 7,4 %.
In the gut, blockage of the tubes from the pancreas and the liver as well as the production of abnormal digestive juices slows down the digestion of food and causes poor growth.
V črevesju zapora vodov iz trebušne slinavke in jeter ter tvorba neobičajnih prebavnih sokov upočasni prebavo hrane in povzroča slabšo rast.
In the HBeAg positive subjects randomised to emtricitabine plus tenofovir disoproxil fumarate, 13 of 68 subjects (19%) experienced HBeAg loss, and 7 of 68 subjects (10%) experienced anti-HBe seroconversion through week 240.
Pri bolnikih, pozitivnih na HBeAg, randomiziranih za emtricitabin in dizoproksiltenofovirijev fumarat, je imelo 13 od 68 bolnikov (19%) izgubo HBeAg in 7 od 68 bolnikov (10%) je imelo serološko konverzijo anti-HBe do konca 240. tedna.
In the HD-Dex arm, median PFS time was 8.0 weeks (95% CI: 7.0, 9.0); the estimated 26-week event-free survival rate was 12.15% (±3.63%).
V skupini VO-deks je bil mediani čas PFS 8,0 tednov (95 % IZ: 7,0; 9,0); ocenjena 26-tedenska stopnja preživetja brez dogodkov je bila 12,15 % (± 3,63 %).
In the hip and knee studies, there was some evidence that the 220 mg dose may be more effective than the 150 mg dose.
V študijah pri vstavitvi umetnega kolka in kolena so nekateri izsledki pokazali, da je 220-miligramski odmerek morda učinkovitejši od 150-miligramskega odmerka.
In the HORIZON - Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
V študiji HORIZON – študiji pomembnih zlomov (Pivotal Fracture Trial [PFT], glejte poglavje 5.1) je bila skupna incidenca atrijske fibrilacije pri bolnikih, ki so prejemali zoledronsko kislino, 2,5 % (pri 96 od 3.862 bolnikov), pri bolnikih, ki so prejemali placebo, pa 1,9 % (pri 75 od 3.852 bolnikov.
In the HORIZON – Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving Aclasta and placebo, respectively.
V študiji HORIZON – študiji pomembnih zlomov (Pivotal Fracture Trial [PFT], glejte poglavje 5.1) je bila skupna incidenca atrijske fibrilacije pri bolnikih, ki so prejemali zdravilo Aclasta, 2,5 % (pri 96 od 3.862 bolnikov), pri bolnikih, ki so prejemali placebo, pa 1,9 % (pri 75 od 3.852 bolnikov).
In the HORIZON – Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
V študiji HORIZON – študiji pomembnih zlomov (Pivotal Fracture Trial [PFT], glejte poglavje 5.1) je bila skupna incidenca atrijske fibrilacije pri bolnikih, ki so prejemali zoledronsko kislino, 2,5 % (pri 96 od 3.862 bolnikov), pri bolnikih, ki so prejemali placebo, pa 1,9 % (pri 75 od 3.852 bolnikov).
In the HORIZON-RFT study Aclasta treatment significantly increased BMD at the total hip and femoral neck relative to treatment with placebo at all timepoints.
V študiji HORIZON-RFT je zdravljenje z zdravilom Aclasta ob vseh časih opazovanja pomembno povečalo mineralno gostoto kosti celotnega kolka in vratu stegnenice v primerjavi s placebom.
In the HORIZONS study, thrombocytopenia was reported in 26 (1. 6%) of bivalirudin-treated patients and in 67 (3.9%) of patients treated with heparin plus a GP IIb/IIIa inhibitor.
O trombocitopeniji so pri bolnikih, ki so sodelovali pri študiji HORIZONS, poročali pri 26 bolnikih (1,6%), ki so jih zdravili z, ter pri 67 (3,9 %) bolnikih, ki so bili zdravljeni s heparinom in zaviralcem GP IIb/IIIa.
In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/m2/day subcutaneously in combination with subcutaneous Ara-C 20 mg/m2/day for 10 days/month.
Na kraku z IFN so bili bolniki zdravljeni 10 dni na mesec s tarčnim odmerkom IFN 5 MIU/m2/dan subkutano v kombinaciji s subkutanim Ara-C 20 mg/m2/dan.
In the IFUM trial, mutation status was assessed in tumour and ctDNA samples derived from plasma, using the Therascreen EGFR RGQ PCR kit (Qiagen).
V preskušanju IFUM so mutacijsko stanje v vzorcih tumorja in iz plazme dobljenih vzorcih ctDNK testirali s kompletom Therascreen EGFR RGQ PCR (Qiagen).
In the iloprost group the NYHA class was improved in 26% of patients (placebo: 15%) (p = 0.032), unchanged in 67.7% of patients (placebo: 76%) and deteriorated in 6.3% of patients (placebo: 9%).
V skupini z iloprostom se je razred po klasifikaciji NYHA izboljšal pri 26 % bolnikov (placebo 15 %) (p = 0,032), ostal nespremenjen pri 67,7 % bolnikov (placebo 76 %) in se poslabšal pri 6,3 % bolnikov (placebo 9 %).
In the imatinib arm, patients were treated with 400 mg daily.
Na kraku z imatinibom so bili bolniki zdravljeni s 400 mg na dan.
In the immediate-release exenatide arm the insulin dose increased by 13 units/day compared to 20 units/day on the placebo arm.
Pri zdravljenju z eksenatidom v obliki s takojšnjim sproščanjem je bil odmerek insulina povišan za 13 enot/dan, pri placebu pa za 20 enot/dan.
In the immunogenicity study, Synflorix produced a similar response to the comparator vaccine for the majority of the S. pneumoniae polysaccharides they share in common.
V študiji imunogenosti se je cepivo Synflorix odzvalo podobno kot primerjalno cepivo za večino polisaharidov bakterije S. pneumoniae, ki so jima skupni.
In the ImproveR registry bolus dosing (without subsequent infusion) was observed in EU clinical practice.
V klinični praksi EU so poročali dajanju bolusa (brez naknadne infuzije).
In the in vitro mouse lymphoma assay, eltrombopag was marginally positive (< 3-fold increase in mutation frequency).
Pri in vitro testu na mišjem limfomu je bil eltrombopag mejno pozitiven (< 3- kratno povečanje pogostnosti mutacij).
In the in vitro whole blood assay in cats, the selectivity of robenacoxib was approximately 500 fold higher for COX-2 (IC50 0.058 μM) as compared to COX-1 (IC50 28.9 μM).
Raziskave celokupne krvi pri mačkah in vitro so pokazale, da je selektivnost robenakoksiba približno 500-krat večja za COX-2 (IC50 0,058 μM) kot za COX-1 (IC50 28,9 μM).
In the indication of major elective orthopaedic surgery: severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
Pri indikaciji "večji elektivni ortopedski kirurški posegi": huda koronarna, periferna arterijska, karotidna ali cerebrovaskularna bolezen, vključno z bolniki, ki so nedavno preboleli miokardni infarkt ali cerebrovaskularni dogodek.
In the individualised interval arm, subjects received ALPROLIX for routine prophylaxis at a fixed dose of 100 IU/kg in a dosing interval starting at every 10 days.
V kraku z individualiziranim intervalom so osebe prejemale zdravilo ALPROLIX za redno profilakso v fiksnem odmerku 100 i.e./kg v intervalih odmerjanja, ki so se začeli vsakih 10 dni.
In the individualised prophylaxis arm, subjects started with a twice weekly regimen consisting of 25 IU/kg on the first day followed by 50 IU/kg on the fourth day.
V individualiziranem profilaktičnem kraku so osebe začele z režimom dvakrat na teden, sestavljenim iz 25 i.e./kg na prvi dan, ki mu je sledilo 50 i.e./kg na četrti dan.
In the iNHL pivotal trial, GAO4753g, two patients in the G+B arm had a positive HAHA (Human Anti-Human Antibody) assessment at baseline and experienced IRRs.
V ključni študiji pri iNHL, GAO4753g, sta dva bolnika v skupini G + B imela pozitivno HAHA (Human Anti-Human Antibody) oceno ob izhodišču in imela reakcije, povezane z infuzijo.
In the initial study comparing Ferriprox with deferoxamine, the average blood ferritin levels were similar in the two treatment groups.
V začetni študiji, v kateri so primerjali zdravilo Ferriprox z deferoksaminom, so bile povprečne ravni feritina v krvi v obeh zdravljenih skupinah podobne.
In the INOT27 trial, 795 preterm infants (GA<29 weeks) with hypoxic respiratory failure were randomised to receive either INOmax (n=395) in a dose of 5 ppm or nitrogen (placebo n=400), beginning within the first 24 hours of life and treated for at least 7 days, up to 21 days.
V preskušanju INOT27 so 795 nedonošenčkov (gestacijska starost < 29 tednov) s hipoksično odpovedjo dihal naključno razporedili v skupini, ki sta prejemali zdravilo INOmax (n = 395) v odmerku 5 ppm oziroma dušik (placebo n = 400) v prvih 24 urah življenja in ki so se zdravili od 7 do 21 dni.
In the INPULSIS trials no increased risk of gastrointestinal perforation was observed in nintedanib treated patients.
V preskušanjih INPULSIS niso opazili povečanega tveganja za predrtje prebavil pri bolnikih, zdravljenih z nintedanibom.
In the integrated analyses, 243 patients were treated with EVARREST and 110 patients were treated with control treatment.
V integriranih analizah je bilo z zdravilom EVARREST zdravljenih 243 bolnikov,110 bolnikov pa je prejemalo kontrolno zdravljenje.
In the integrated data, 26.5% in the JETREA group compared with 10.1% in the placebo group achieved VMA resolution at Day 28 (p<0.001).
V integriranih podatkih je 26,5 % bolnikov v skupini z zdravilom JETREA v primerjavi z 10,1 % bolnikov v skupini s placebom 28. dan doseglo odpravo VMA (p <0,001).
In the intent to treat (all randomised) population, the median age was 63 years (range 31-87 years), 57 % were males, and 61% were White and 33% were Asian.
V populaciji z namenom zdravljenja (celotni randomizirani populaciji) je bila mediana starost 63 let (razpon 31 – 87 let), 57 % je bilo moških ter 61 % belcev in 33 % oseb azijskega porekla.
In the intent to treat and on treatment analyses the proportion of patients with HIV RNA of
V analizi populacije, ki so jo nameravali zdraviti, je imelo HIV
In the intent-to-treat (ITT) population, 70% of patients in the abacavir group, compared to 69% of patients in the zidovudine group, achieved a virologic response of plasma HIV-1 RNA 50 copies/ml by Week 48 (point estimate for treatment difference: 0.8, 95% CI -6.3, 7.9).
V populaciji vseh vključenih bolnikov (ITT population – »intet-to-treat population«) je bil pri 70 % bolnikov, ki so prejemali abakavir, in pri 69 % bolnikov, ki so prejemali zidovudin ,v 48. tednu dosežen virusni odziv s plazemsko HIV-1 RNA  50 kopij/ml (ocenjena vrednost v razliki zdravljenja: 0,8; 95 % interval zaupanja; -6,3; 7,9).
In the intent-to-treat (ITT) population, 70% of patients in the abacavir group, compared to 69% of patients in the zidovudine group, achieved a virologic response of plasma HIV-1 RNA 50 copies/ml by Week 48 (point estimate for treatment difference: 0.8, 95% CI -6.3, 7.9).
V populaciji vseh vključenih bolnikov (ITT population – »intet-to-treat population«) je bil pri 70 % bolnikov, ki so prejemali abakavir, in pri 69 % bolnikov, ki so prejemali zidovudin, v 48. tednu dosežen virusni odziv s plazemsko HIV-1 RNA 50 kopij/ml (ocenjena vrednost v razliki zdravljenja: 0,8; 95 % interval zaupanja; -6,3; 7,9).
In the intent-to-treat analysis, a CR rate of 23.6% (95% CI: 13.2, 37) was observed in 13/55 subjects treated with Dacogen.
V populaciji z namenom zdravljenja je bil pri bolnikih, ki so prejemali Dacogen, delež tistih, ki so dosegli popolno remisijo, 23,6% (95-odstotni IZ: 13,2; 37)(13/55).
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Pri analizi vključenih bolnikov (intention to treat analysis) so v skupini, ki je jemala klopidogrel, opazili 939 dogodkov, v skupini, ki je jemala ASA, pa 1.020 dogodkov (zmanjšanje relativnega tveganja /RT/: 8,7%%, 95-odstotni interval zaupanja /IZ/: 0,2 do 16,4; p = 0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 (IZ: 0 do 20) bolnikom.